Canadian Cancer Trials Group Bulletins


Chair and Chair-Elect of the IND Committee

The Investigational New Drug (IND) Committee has a systematic process to identify leadership of the Committee. The process begins with selection of an Incoming Chair, who subsequently takes on the leadership position of Chair. In 2008, Dr. Kim Chi from the British Columbia Cancer Agency assumed the role of Incoming Chair and began his term as Chair in 2010. In her new role as Director of the IND Program, Dr. Lesley Seymour has asked Kim to stay on as Chair for an additional term of one year. Kim has kindly agreed to do so. We thank him for his leadership and for his ongoing efforts on behalf of the Canadian Cancer Trials Group.

Based on recommendations from the IND Committee, we are very pleased to announce that Dr. Scott Laurie from the Ottawa Regional Cancer Centre and University of Ottawa will now take on the role of an Incoming Chair. Scott received his MD from the University of Ottawa in 1994 and after completing residency training and a subsequent research fellowship in Thoracic Oncology at Memorial Sloan-Kettering Cancer Centre in New York, he returned to Ottawa and has been a medical oncologist within the University of Ottawa system since 2000. Scott has had extensive leadership roles within Canadian Cancer Trials Group including Study Chair roles of BR.23, BR.24, BR.29, and IND.171 and IND.183. He has been a leading contributor to our IND Program.

Scott will transition from being Incoming Chair to Chair of the IND Committee in the Fall of 2013.
We wish to thank Scott for taking on this new responsibility and for the leadership he will provide.